'It was not easy' - EMA policy chief on new trial data disclosure policy
This article was originally published in SRA
Executive Summary
Few people in the drug regulatory sphere can be unaware of the travails that have beset the European Medicines Agency's controversial policy on the proactive disclosure of clinical trial data, which has been two and a half years in the making and will come into effect at the beginning of next year1.
You may also be interested in...
Industry & Regulators To Align Advice on COVID-19 Vaccine Updates
A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.
Denmark Planning To Impose Drug Stockpiling Obligations From July
A new bill is intended to address the increase in medicine supply problems in Denmark in recent years.
National Drug Stockpiles Create ‘False Sense Of Security’
The generics and biosimilars industry body Medicines for Europe says disparate national stockpiling requirements are not a solution to shortages and can bring “significant risks” for the supply chain and access to medicines.